A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
At a glance
- Drugs JNJ 55375515 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 28 Sep 2018 Status changed from recruiting to completed.
- 31 Jul 2018 Planned primary completion date changed from 10 Jul 2018 to 10 Sep 2018.
- 29 Jun 2018 Planned End Date changed from 10 Jul 2018 to 10 Sep 2018.